Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Gapchenko AS"'
Autor:
V. V. Ptushkin, A. D. Kulagin, E. A. Lukina, I. L. Davydkin, T. S. Konstantinova, V. S. Shamrai, N. V. Minaeva, D. A. Kudlay, E. V. Gapchenko, O. A. Markova, A. Yu. Borozinets
Publikováno v:
Терапевтический архив, Vol 92, Iss 7, Pp 77-84 (2020)
Currently, the main pathogenetic method for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) is the treatment with recombinant monoclonal antibodies that block the C5 component of the complement system. Eculizumab is the first biotechnologi
Externí odkaz:
https://doaj.org/article/c8727c8295774e18b3a446395b05b823
Autor:
S. B. Fitilev, A. V. Vozzhaev, I. I. Shkrebneva, D. A. Kudlay, E. V. Gapchenko, O. A. Markova, A. Yu. Borоzinets, A. A. Kazarov, М. S. Pantyushenko
Publikováno v:
Онкогематология, Vol 14, Iss 4, Pp 73-83 (2019)
Background. Currently, the main treatment for Gaucher disease is enzyme replacement therapy. Recombinant glucocerebrosidase (imiglu-cerase) is the first biotechnological drug for enzyme replacement therapy with proven clinical efficacy and safety for
Externí odkaz:
https://doaj.org/article/3727d50786d248acb2c75158dae94797
Autor:
Elena L Amelina, Stanislav A Krasovsky, Nina E Akhtyamova-Givirovskaya, Nataliya Yu Kashirskaya, Diana I Abdulganieva, Irina K Asherova, Ilya E Zilber, Liliya S Kozyreva, Lubov M Kudelya, Natalya D Ponomareva, Nataliya P Revel-Muroz, Elena M Reutskaya, Tatiana A Stepanenko, Gulnara N Seitova, Olga P Ukhanova, Olga V Magnitskaya, Dmitry A Kudlay, Oksana A Markova, Elena V Gapchenko
Publikováno v:
PLoS ONE, Vol 16, Iss 12, p e0261410 (2021)
BackgroundPatients with cystic fibrosis (CF) need costly medical care and adequate therapy with expensive medicinal products. Tigerase® is the first biosimilar of dornase alfa, developed by the lead Russian biotechnology company GENERIUM. The aim of
Externí odkaz:
https://doaj.org/article/e8737b56062f40718a177ef1474c9033
Autor:
Natalia Petruk, Olena Gapchenko
Publikováno v:
Visnyk of the Lviv University Series Philosophical Sciences. :143-149
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1afdcfc22fd74db1bf14810e3ab08cea
https://doi.org/10.30970/phs.2022.29.14
https://doi.org/10.30970/phs.2022.29.14
Autor:
Julia Prysyazhna-Gapchenko
In the article rare editions of magazine type are first probed for peasants which nursed in an environment the Ukrainian emigrants in the first post-war years on territory of the American area of occupation in Germany, and also in the USA. Separately
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d6283b9fd21dfcd3aadce3d33440aa7
https://doi.org/10.30970/vjo.2023.52-53.11720
https://doi.org/10.30970/vjo.2023.52-53.11720
Autor:
A.Yu. Borozinets, E.V. Gapchenko, K.G. Kopylov, S.N. Farafonova, M.A. Timofeeva, E.E. Shiller, V.V. Lebedev, Immunology named after Dmitry Rogachev, Moscow, Russia, N.I. Zozulya, Dmitry Kudlay, V.M. Chernov, E.P. Ivashkina, O.I. Plaksina, T.V. Asekretova, O.A. Markova
Publikováno v:
Pediatria. Journal named after G.N. Speransky. 100:154-161
The purpose of the study was to assess the efficacy, safety and pharmacokinetics of the moroctocog alfa (Octofactor) in children aged 2-6 with haemophilia A. Materials and methods of research : six patients between 2 and 6 years of age (average age 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c78db7afa429209d8213bce87eb5b84f
https://doi.org/10.24110/0031-403x-2021-100-6-154-161
https://doi.org/10.24110/0031-403x-2021-100-6-154-161
Autor:
N.V. Shcherbakova, E.V. Kalinina, V.Yu. Petrov, I.N. Lavrentieva, G.N. Mustafina, M.V. Kosinova, E.V. Gapchenko, E.E. Shiller, A.V. Rogov, S.N. Duryagina, O.A. Markova, A.Yu. Borozinets, Pavel Svirin, K.S. Aslanyan, E.N. Lemazina, Vladimir Vdovin, Dmitry Kudlay, M.A. Timofeeva
Publikováno v:
Pediatria. Journal named after G.N. Speransky. 100:159-169
The main method of treatment for hemophilia A is replacement therapy with drugs of blood coagulation factors VIII (FVIII). The active use of biotechnological methods in the production of recombinant drugs contributes to the development and registrati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::450fda3121a7415f2edb2fe766dd29e0
https://doi.org/10.24110/0031-403x-2021-100-5-159-169
https://doi.org/10.24110/0031-403x-2021-100-5-159-169
Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab
Autor:
Kulagin, Alexander D., Ptushkin, Vadim V., Lukina, Elena A., Davydkin, Igor L., Korobkin, Alexander V., Shamrai, Vladimir S., Konstantinova, Tatyana S., Kaporskaya, Tatyana S., Mitina, Tatyana A., Ksenzova, Tatyana I., Zuev, Evgeny V., Markova, Oksana A., Gapchenko, Elena V., Kudlay, Dmitry A.
Publikováno v:
Annals of Hematology
Currently, eculizumab is the main effective treatment for paroxysmal nocturnal hemoglobinuria (PNH). The aim of this randomized multicenter noninferiority study was to evaluate the efficacy and safety of the Biosimilar (Elizaria) in comparison with t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4e6bcc2cf84bb5e5f891556400dbf89
https://doi.org/10.1007/s00277-021-04624-7
https://doi.org/10.1007/s00277-021-04624-7
Autor:
L.G. Basalaeva, V.M. Chernov, M.A. Timofeeva, E.V. Gapchenko, N.I. Zozulya, V. V. Shkryabunova, O.A. Krasheninnikova, I.N. Lavrentieva, T.V. Asekretova, A.Yu. Borozinets, O.A. Markova, Tatiana Andreeva, V.Yu. Petrov, K.G. Kopylov, Dmitry Kudlay, A.A. Rumyantsev, Saint Petersburg City Polyclinic No. , Saint Petersburg, Russia, E.E. Shiller, Igor Kurtov, Pavel Svirin, I.A. Lavrichenko, A.N. Mamaev, Vladimir Vdovin, Immunology named after Dmitry Rogachev, Moscow, Russia, Childhood Protection, Barnaul, Altai Krai, Russia, I.L. Davydkin, V.V. Lebedev
Publikováno v:
Pediatria. Journal named after G.N. Speransky. 100:236-245
Currently, the main method of treatment for hemophilia A is replacement therapy with drugs of blood coagulation factors VIII (FVIII). As a result of the development of new production technologies, recombinant FVIII are increasingly used for the treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::032327e128ad9fa191b6fec507848f1e
https://doi.org/10.24110/0031-403x-2021-100-2-236-245
https://doi.org/10.24110/0031-403x-2021-100-2-236-245
Autor:
Natalia Petruk, Olena Gapchenko
Publikováno v:
Visnyk of the Lviv University. :22-29
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99bd5549627aa23efe8efe34b9f446bb
https://doi.org/10.30970/pps.2021.39.3
https://doi.org/10.30970/pps.2021.39.3